Anixa Biosciences Reports 74% Immune Response and Lira-Cel Survival Data
Anixa Biosciences’ breast cancer vaccine achieved primary endpoints with protocol-defined immune responses in 74% of participants during its Phase 1 trial. Its ovarian cancer CAR-T therapy, lira-cel, also showed positive survival outcomes in ongoing Phase 1 testing and will be discussed at an investor conference on April 16.
1. Conference Participation
Dr. Amit Kumar, Chairman and CEO, will present Anixa’s business model, pipeline strategy and recent clinical milestones at a virtual biotech investor conference on April 16, 2026, at 3:30 pm ET.
2. Breast Cancer Vaccine Phase 1 Results
Anixa’s Phase 1 breast cancer vaccine trial met its primary endpoints by inducing protocol-defined immune responses in 74% of participants, marking a key proof-of-concept for its Cleveland Clinic–licensed vaccine technology targeting retired tumor proteins.
3. Ovarian Cancer CAR-T Therapy Data
Its ovarian cancer CAR-T candidate, lira-cel, delivered positive survival data in an ongoing Phase 1 study, leveraging novel chimeric endocrine receptor-T cell (CER-T) technology developed in collaboration with Moffitt Cancer Center.